NO20091579L - Nye 5,7-disubstituerte [1,3]tiazolo[4,5-d]pyrimidin-2(3H)-onderivater og deres anvendelse i terapi - Google Patents

Nye 5,7-disubstituerte [1,3]tiazolo[4,5-d]pyrimidin-2(3H)-onderivater og deres anvendelse i terapi

Info

Publication number
NO20091579L
NO20091579L NO20091579A NO20091579A NO20091579L NO 20091579 L NO20091579 L NO 20091579L NO 20091579 A NO20091579 A NO 20091579A NO 20091579 A NO20091579 A NO 20091579A NO 20091579 L NO20091579 L NO 20091579L
Authority
NO
Norway
Prior art keywords
thiazolo
disubstituted
therapy
derivatives
new
Prior art date
Application number
NO20091579A
Other languages
English (en)
Norwegian (no)
Inventor
Gunnar Nordvall
Tobias Rein
Can Slivo
Annika Kers
Rolf Johansson
Sofia Karlstrom
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39230456&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20091579(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20091579L publication Critical patent/NO20091579L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • AIDS & HIV (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
NO20091579A 2006-09-29 2009-04-21 Nye 5,7-disubstituerte [1,3]tiazolo[4,5-d]pyrimidin-2(3H)-onderivater og deres anvendelse i terapi NO20091579L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82746006P 2006-09-29 2006-09-29
US82812506P 2006-10-04 2006-10-04
PCT/SE2007/000857 WO2008039138A1 (en) 2006-09-29 2007-09-27 Novel 5, 7-disubstituted [1, 3 ] thiazolo [4, 5-d] pyrimidin-2 (3h)-one derivatives and their use in therapy

Publications (1)

Publication Number Publication Date
NO20091579L true NO20091579L (no) 2009-04-21

Family

ID=39230456

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091579A NO20091579L (no) 2006-09-29 2009-04-21 Nye 5,7-disubstituerte [1,3]tiazolo[4,5-d]pyrimidin-2(3H)-onderivater og deres anvendelse i terapi

Country Status (21)

Country Link
US (2) US7960395B2 (de)
EP (1) EP2069364B1 (de)
JP (1) JP5422386B2 (de)
KR (1) KR101345085B1 (de)
AR (1) AR063023A1 (de)
AT (1) ATE537177T1 (de)
AU (1) AU2007300748B2 (de)
BR (1) BRPI0717109A2 (de)
CA (1) CA2664789A1 (de)
CL (1) CL2007002813A1 (de)
CO (1) CO6150165A2 (de)
ES (1) ES2377469T3 (de)
IL (1) IL197293A0 (de)
MX (1) MX2009003005A (de)
NO (1) NO20091579L (de)
NZ (1) NZ576520A (de)
PE (1) PE20080973A1 (de)
RU (1) RU2441012C2 (de)
TW (1) TW200820973A (de)
UY (1) UY30612A1 (de)
WO (1) WO2008039138A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR071036A1 (es) * 2008-03-26 2010-05-19 Astrazeneca Ab Derivados 5, 7-disustituidos de [1, 3]tiazolo[4, 5-d]pirimidin-2 (3h)-ona, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por el receptor cx3cr1.
US8476301B2 (en) 2011-09-13 2013-07-02 Eisai R&D Management Co., Ltd. Pyrrolidin-3-ylacetic acid derivative
TWI543975B (zh) 2011-09-13 2016-08-01 Eisai R&D Man Co Ltd Pyrrolidin-3-yl acetic acid derivatives
WO2014142056A1 (ja) 2013-03-12 2014-09-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピロリジン－３－イル酢酸誘導体の塩およびその結晶
GB201811169D0 (en) * 2018-07-06 2018-08-29 Kancera Ab New compounds
PE20251587A1 (es) 2022-10-19 2025-06-16 Astrazeneca Ab 1,3,5-triazinas 2,4,6-trisustituidas como modulares de cx3cr1

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9802729D0 (sv) 1998-08-13 1998-08-13 Astra Pharma Prod Novel Compounds
SE9903544D0 (sv) 1999-10-01 1999-10-01 Astra Pharma Prod Novel compounds
DE60101372T2 (de) * 2000-02-11 2004-10-14 Astrazeneca Ab Pyrimidinverbindungen und ihre verwendung als modulatoren der chemokin-rezeptor-aktivität
GB2359081A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active thiazolopyrimidines
GB2359551A (en) * 2000-02-23 2001-08-29 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
SE0101082D0 (sv) * 2001-03-27 2001-03-27 Astrazeneca Ab Novel use
GB0221828D0 (en) * 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
GB0221829D0 (en) * 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
WO2005033115A1 (en) * 2003-10-07 2005-04-14 Astrazeneca Ab New 2-substituted, 4-amino-thiazolo[4,5-d] pyrimidines, useful as chemokine receptor antagonists, esp. cx3cr1
US20090239882A1 (en) * 2004-12-17 2009-09-24 Astrazeneca Ab Thiazolopyramidine Compounds for the Modulation of Chemokine Receptor Activity
AR053347A1 (es) * 2005-04-06 2007-05-02 Astrazeneca Ab Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos
UA90707C2 (en) 2005-04-06 2010-05-25 Астразенека Аб Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives

Also Published As

Publication number Publication date
RU2441012C2 (ru) 2012-01-27
US20110105537A1 (en) 2011-05-05
EP2069364A1 (de) 2009-06-17
TW200820973A (en) 2008-05-16
ES2377469T3 (es) 2012-03-27
EP2069364B1 (de) 2011-12-14
AR063023A1 (es) 2008-12-23
WO2008039138A8 (en) 2009-03-19
RU2009109100A (ru) 2010-11-10
KR20090057069A (ko) 2009-06-03
KR101345085B1 (ko) 2013-12-31
NZ576520A (en) 2011-08-26
BRPI0717109A2 (pt) 2013-10-08
AU2007300748A1 (en) 2008-04-03
US20080318981A1 (en) 2008-12-25
IL197293A0 (en) 2009-12-24
US7960395B2 (en) 2011-06-14
AU2007300748B2 (en) 2011-09-08
CL2007002813A1 (es) 2008-04-04
ATE537177T1 (de) 2011-12-15
CO6150165A2 (es) 2010-04-20
UY30612A1 (es) 2008-05-02
WO2008039138A1 (en) 2008-04-03
EP2069364A4 (de) 2010-03-24
HK1131389A1 (en) 2010-01-22
PE20080973A1 (es) 2008-10-02
MX2009003005A (es) 2009-04-01
CA2664789A1 (en) 2008-04-03
JP5422386B2 (ja) 2014-02-19
JP2010504962A (ja) 2010-02-18

Similar Documents

Publication Publication Date Title
NO20075610L (no) Nye 5,7-disubstituerte [1,3]tiazol[4,5-d]pyrlmldin-2(3H)-onderivater
NO20075603L (no) Nye 5-substituerte 7-amino[1,3]tiazol[4,5-d]pyrimidinderivater
NO20091577L (no) Nye 5,7-disubstituerte (1,3)tiazolo[4,5-D]pyrimidin-2(3H)-aminderivater og deres anvendelse i terapi
NO20082065L (no) Nye imidazo[4,5-b]pyridinderivater som inhibitorer av glykogensyntasekinase 3 for anvendelse ved behandling av demens og neurodegenerative forstyrrelser
TNSN08478A1 (en) Pyrazolo [3,4-d] pyrimidine derivatives useful to treat respiratory disorders
EA201001188A1 (ru) Связанные мостиковой связью бициклические гетероциклические или спиробициклические гетероциклические производные пиразоло[1,5-a]пиримидинов, способы их получения и их применения
NO20072984L (no) Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for medical treatment
WO2007002293A3 (en) Azaindazole compounds and methods of use
WO2009003669A3 (en) Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for medical treatment
WO2015132799A2 (en) Novel heterocyclic compounds
BR112012010085B1 (pt) composto, quantidade terapeuticamente eficaz de um composto, formulação farmacêutica
SE0402735D0 (sv) Novel compounds
IL210071A0 (en) Triazolo [4,5-d]pyramidine derivatives and their use as purine receptor antagonists
WO2007073432A3 (en) Piperidine derivatives and methods of use
TW200628452A (en) Substituted 2-anilinopyrimidines as cell-cycle-kinase or receptor-tyrosine-kinase inhibitors, their production and use as pharmaceutical agents
JO3319B1 (ar) مركبات 3- (ايميدازول) - بيرازولو (3,4 - b ) بيريدين
UY31734A (es) Nuevos derivados 258 5, 7-disustituidos de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona
MX2009003005A (es) Nuevos derivados 5,7-disustituidos de [1,3] tiazolo [4,5-d]pirimidin-2(3h)-ona y su uso en terapia.
ATE496918T1 (de) Als a2b-adenosinrezeptorantagonisten geeignete 5- phenyl-6-pyridin-4-yl-1,3-dihydro-2h-imidazoä4, - büpyridin-2-onderivate
NO20081082L (no) Nye piperidinderivater som kjemokinreseptorformulatorer som er nyttige for behandling av respiratoriske sykdommer
Hu et al. Synthesis and biological evaluation of novel 5, 6-dihydropyrimido [4, 5-f] quinazoline derivatives as potent CDK2 inhibitors
CA3030429A1 (en) Treatment of cancer
NO20080671L (no) Bisykliske piperaziner som metabotrofiske glutamatreseptorantagonister
UA95811C2 (en) 5,7-disubstituted [1,3]thiazolo [4,5-d] pyrimidin-2 (3h)-one derivatives and their use in therapy
TW200640904A (en) Quinazoline derivatives

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application